OncoEthix In-Licenses OTX015
News Jun 18, 2012
OncoEthix has in-licensed a compound, OTX015, from Mitsubishi Tanabe Pharma Corporation (MTPC).
OTX015 is a synthetic small molecule targeted to BET bromodomains 2/3/4 (BRD2/3/4).
Recent scientific publications have shown that inhibition of BRD2/3/4 down-regulates MYC transcription, followed by genome-wide down regulation of MYC-dependent target genes.
Previously, pharmacological inhibition of MYC-a transcription factor that is a master regulator of diverse cellular functions with a major role in a variety of human neoplasias-was not considered possible.
MTPC had successfully completed Phase 1 clinical studies in healthy volunteers and licensed the compound to OncoEthix to take advantage of its expertise in the development of novel oncology drugs. OncoEthix plans to initiate clinical trials later this year.
Dr Esteban Cvitkovic, Chief Scientific Officer of OncoEthix, noted that “the studies that we performed have confirmed that OTX015 is active across a wide range of hematologic malignancies. I look forward to exploring the compound’s potential in the clinic.”
Dr Kay Noel, Chief Operating Officer who led the licensing effort with Bertrand Damour, Chief Executive Officer, said: “We are excited about the opportunity to lead the exploration of one of the most promising new cancer targets.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE